Robustaflavone

Robustaflavone

SCHEMBL624405

O=c1cc(-c2ccc(O)c(-c3c(O)cc4oc(-c5ccc(O)cc5)cc(=O)c4c3O)c2)oc2cc(O)cc(O)c12.SSSS.[KH]

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 4/20 0.69
MMP3 P08254 2/20 0.69
MMP9 P14780 2/20 0.69
KMT2A Q03164 7/20 0.64
MEN1 O00255 6/20 0.64
TDP1 Q9NUW8 4/20 0.64
THRB P10828 3/20 0.64
PTPN1 P18031 1/20 0.64
CYP1A1 P04798 6/20 0.62
CYP1B1 Q16678 6/20 0.62
ABCB1 P08183 5/20 0.62
POLH Q9Y253 5/20 0.62
ALDH1A1 P00352 5/20 0.62
CYP1A2 P05177 5/20 0.62
MAPT P10636 5/20 0.62
SLCO2B1 O94956 4/20 0.62
FTO Q9C0B1 4/20 0.62
TP53 P04637 4/20 0.62
CYP3A4 P08684 4/20 0.62
CYP2D6 P10635 4/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Robustaflavone SCHEMBL561807 0.94 APP (0.77) APPMMP3MMP9KMT2AMEN1
Robustaflavone SCHEMBL7643511 0.93 APP (0.76) APPMMP3MMP9KMT2AMEN1
Robustaflavone SCHEMBL7638211 0.93 APP (0.76) APPMMP3MMP9KMT2AMEN1
SCHEMBL17166016 0.87 APP (0.70) APPMMP3MMP9KMT2AMEN1
Robustaflavone SCHEMBL7454193 0.85 KMT2A (0.66) APPMMP3MMP9KMT2AMEN1
Robustaflavone SCHEMBL7517639 0.84 APP (0.67) APPMMP3MMP9KMT2AMEN1
Sumaflavone SCHEMBL30152146 0.82 KMT2A (0.74) APPMMP3MMP9KMT2AMEN1
Sumaflavone SCHEMBL13980979 0.82 KMT2A (0.74) APPMMP3MMP9KMT2AMEN1
Amentoflavone SCHEMBL312563 0.82 MEN1 (0.80) APPMMP3MMP9KMT2AMEN1
Amentoflavone SCHEMBL29929632 0.82 MEN1 (0.80) APPMMP3MMP9KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2603225-A2 ELECTRONICALLY MODIFIED REACTION INTERMIDEATES Markou, Demetrios (US) 2013-06-19 EP claimed
WO-2012024196-A2 A NOVEL METHOD FOR CREATING, SUSPENDING AND STABILIZING ELECTRONICALLY MODIFIED REACTION INTERMIDEATES MARKOU DEMETRIOS (US) 2012-02-23 WO claimed
US-20120039796-A1 Novel method for creating, suspending and stabilizing electronically modified oxygen derivatives, along with creating, suspending and stabilizing electronically modified reaction intermediates, in a bio compatible fluorocarbon suspension, for the purpose of inducing a cascading immune response in mammalian patients MARKOU DEMETRIOS (US) 2012-02-16 US claimed
EP-0833631-B1 ROBUSTAFLAVONE AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS ADVANCED LIFE SCIENCES INC (US) 2002-11-13 EP claimed
US-20020068757-A1 Biflavanoids and derivatives thereof as antiviral agents ADVANCED LIFE SCIENCES, INC. 2002-06-06 US claimed
US-6399654-B1 ADMINISTERING MIXTURE OF VIRICIDE AND BIOFLAVANOID ADVANCED LIFE SCIENCES, INC. 2002-06-04 US claimed
WO-1998046238-A1 BIFLAVINOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS, ALONE OR IN COMBINATION WITH AT LEAST ONE KNOWN ANTIVIRAL AGENT MEDICHEM RESEARCH, INC. (US) 1998-10-22 WO claimed
US-5773462-A INFLUENZA THERAPY MEDICHEM RESEARCH, INC. (US) 1998-06-30 US claimed
EP-0833631-A1 BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS MEDICHEM RESEARCH, INC. (US) 1998-04-08 EP claimed
WO-1997000679-A1 BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS MEDICHEM RESEARCH, INC. (US) 1997-01-09 WO claimed
EP-1245230-A3 Amentoflavone as an antiviral agent Advanced Life Sciences Inc. (US) 2003-11-26 EP disclosed
EP-0833631-B1 ROBUSTAFLAVONE AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS ADVANCED LIFE SCIENCES INC (US) 2002-11-13 EP disclosed
EP-0833631-B1 ROBUSTAFLAVONE AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS ADVANCED LIFE SCIENCES INC (US) 2002-11-13 EP disclosed
EP-1245230-A2 Amentoflavone as an antiviral agent Advanced Life Sciences Inc. (US) 2002-10-02 EP disclosed
EP-1245230-A2 Amentoflavone as an antiviral agent Advanced Life Sciences Inc. (US) 2002-10-02 EP disclosed
US-5773462-A INFLUENZA THERAPY MEDICHEM RESEARCH, INC. (US) 1998-06-30 US disclosed
EP-0833631-A1 BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS MEDICHEM RESEARCH, INC. (US) 1998-04-08 EP disclosed
EP-0833631-A1 BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS MEDICHEM RESEARCH, INC. (US) 1998-04-08 EP disclosed
WO-1997000679-A1 BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS MEDICHEM RESEARCH, INC. (US) 1997-01-09 WO disclosed
WO-1997000679-A1 BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS MEDICHEM RESEARCH, INC. (US) 1997-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068757-A1 Biflavanoids and derivatives thereof as antiviral agents HK2, GYS2, HK1 APP 4657/4885MMP3 2628/4885MMP9 4056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.